Clinical trials: Diuretic Effect
Heart Failure
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as…
- Trial name
- NCT01439009
- Testing
- Tolvaptan
- Where
- 8 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes.
- Trial name
- NCT00671424
- Testing
- Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
- Trial name
- NCT04763226
- Testing
- BMS-986308, Furosemide
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Congestive
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00328692
- Testing
- rolofylline
- Volunteers
- 932 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Heart Failure, Congestive
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening…
- Trial name
- REACH UP (NCT00443690)
- Testing
- rolofylline
- Volunteers
- 480 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
- Trial name
- NCT00277472
- Testing
- Valsartan/Hydrochlorothiazide, HCTZ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis
Cardiac Edema
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day…
- Trial name
- NCT00544869
- Testing
- OPC-41061 （Tolvaptan)
- Where
- 6 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hypertension
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00364026
- Testing
- darusentan
- Sponsor
- Gilead Sciences
Bioavailability Heathy Volunteers
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
- Trial name
- NCT07043634
- Testing
- FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Diabetes Mellitus
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.
- Trial name
- NCT00306696
- Testing
- Rosiglitazone, spironolactone, hydrochlorothiazide
- Where
- 46 sites in Belgium, Canada and 12 more
- Volunteers
- 388 people
- Sponsor
- GlaxoSmithKline
Congestive Heart Failure, Renal Impairment
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
- Trial name
- NCT00652782
- Testing
- rolofyline
- Volunteers
- 160 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hypertension
Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.
Primary objective:To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension.
- Trial name
- NCT00334386
- Testing
- Torasemide Prolonged Release (loop diuretic), Torasemide Immediate Release (loop diuretic)
- Volunteers
- 388 people
- Sponsor
- Ferrer Internacional S.A.
Uncontrolled Hypertension
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average…
- Trial name
- BaxNoD (NCT07686120)
- Testing
- baxdrostat 2mg
- Where
- 51 sites in China
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Congestive Heart Failure
Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined…
- Trial name
- TORAFIC (NCT00409942)
- Testing
- Torasemide Prolonged Release, Furosemide
- Where
- 23 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Ferrer Internacional S.A.
Heart Failure, Congestive, Renal Insufficiency
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
- Trial name
- NCT00159614
- Testing
- KW-3902IV
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Heart Failure, Congestive
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are…
- Trial name
- NCT00159627
- Testing
- KW-3902IV
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)